BASILEA PHARMACEUTICA: Proof-of-concept established in monotherapy in iCCA for Derazantinib | | CHF102(+92%)
BASILEA PHARMACEUTICA - | CHF102(+92%)Proof-of-concept established in monotherapy in iCCA for Derazantinib
Positive top-line results of FIDES-01 confirm derazantinib’s potential
Is dera relevant in iCCA without the full data on other aberrations ?
What’s next?
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.